Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ABEO's Cash-to-Debt is ranked higher than
98% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ABEO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ABEO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.12 Max: No Debt
Current: No Debt
Equity-to-Asset 0.94
ABEO's Equity-to-Asset is ranked higher than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ABEO: 0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
ABEO' s Equity-to-Asset Range Over the Past 10 Years
Min: -118.34  Med: -0.23 Max: 0.94
Current: 0.94
-118.34
0.94
Piotroski F-Score: 4
Altman Z-Score: 74.06
Beneish M-Score: -3.30
WACC vs ROIC
18.26%
-78.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2838.04
ABEO's Operating Margin % is ranked lower than
85% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ABEO: -2838.04 )
Ranked among companies with meaningful Operating Margin % only.
ABEO' s Operating Margin % Range Over the Past 10 Years
Min: -12105.26  Med: -1697.98 Max: -98
Current: -2838.04
-12105.26
-98
Net Margin % -2946.58
ABEO's Net Margin % is ranked lower than
85% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ABEO: -2946.58 )
Ranked among companies with meaningful Net Margin % only.
ABEO' s Net Margin % Range Over the Past 10 Years
Min: -38147.37  Med: -2013.67 Max: 217.87
Current: -2946.58
-38147.37
217.87
ROE % -29.58
ABEO's ROE % is ranked higher than
56% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ABEO: -29.58 )
Ranked among companies with meaningful ROE % only.
ABEO' s ROE % Range Over the Past 10 Years
Min: -40.05  Med: -33.14 Max: -26.22
Current: -29.58
-40.05
-26.22
ROA % -26.81
ABEO's ROA % is ranked higher than
55% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ABEO: -26.81 )
Ranked among companies with meaningful ROA % only.
ABEO' s ROA % Range Over the Past 10 Years
Min: -602.71  Med: -212.41 Max: 379.77
Current: -26.81
-602.71
379.77
ROC (Joel Greenblatt) % -3536.93
ABEO's ROC (Joel Greenblatt) % is ranked lower than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ABEO: -3536.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABEO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -523920  Med: -12054.1 Max: 72738.46
Current: -3536.93
-523920
72738.46
3-Year Revenue Growth Rate -81.40
ABEO's 3-Year Revenue Growth Rate is ranked lower than
89% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ABEO: -81.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABEO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -81.4 Max: 198.1
Current: -81.4
0
198.1
GuruFocus has detected 2 Warning Signs with Abeona Therapeutics Inc ABEO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABEO's 30-Y Financials

Financials (Next Earnings Date: 2018-04-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ABEO Guru Trades in Q4 2016

Paul Tudor Jones 33,500 sh (New)
Chuck Royce 312,221 sh (-16.70%)
George Soros 896,642 sh (-38.68%)
» More
Q1 2017

ABEO Guru Trades in Q1 2017

Louis Moore Bacon 150,000 sh (New)
Paul Tudor Jones 33,500 sh (unchged)
Chuck Royce 312,221 sh (unchged)
George Soros 896,642 sh (unchged)
» More
Q2 2017

ABEO Guru Trades in Q2 2017

Chuck Royce 312,221 sh (unchged)
George Soros 896,642 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon 100,000 sh (-33.33%)
» More
Q3 2017

ABEO Guru Trades in Q3 2017

Andreas Halvorsen 2,238,720 sh (New)
Steven Cohen 206,857 sh (New)
Paul Tudor Jones 32,108 sh (New)
George Soros Sold Out
Chuck Royce 227,221 sh (-27.22%)
Louis Moore Bacon 25,000 sh (-75.00%)
» More
» Details

Insider Trades

Latest Guru Trades with ABEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-09-30 Sold Out 0.13%$6.6 - $17.2 $ 16.1050%0
George Soros 2016-12-31 Reduce -38.68%0.12%$4.25 - $8.7 $ 16.10157%896,642
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2834
Compare:NAS:FPRX, NAS:IMGN, XKRX:096530, ROCO:4105, TSX:PLI, NAS:ADAP, NAS:CTMX, NAS:NTLA, ROCO:4162, NAS:LJPC, HKSE:06826, NYSE:MYOV, NAS:ANIK, HKSE:01681, BOM:540701, TSE:2931, SZSE:002604, XPAR:GNFT, NAS:ASMB, NAS:RVNC » details
Traded in other countries:PCJP.Germany,
Headquarter Location:USA
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB.

Top Ranked Articles about Abeona Therapeutics Inc

Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
Abeona Therapeutics Announces Public Offering of Common Stock
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
Andreas Halvorsen Dives into Deciphera Pharma Company launches initial public offering and reports recent study results
Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks. Read more...
Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa

Ratios

vs
industry
vs
history
PB Ratio 7.30
ABEO's PB Ratio is ranked lower than
74% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ABEO: 7.30 )
Ranked among companies with meaningful PB Ratio only.
ABEO' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.59 Max: 55.44
Current: 7.3
1.16
55.44
PS Ratio 731.78
ABEO's PS Ratio is ranked lower than
96% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ABEO: 731.78 )
Ranked among companies with meaningful PS Ratio only.
ABEO' s PS Ratio Range Over the Past 10 Years
Min: 1.27  Med: 65.07 Max: 2740.96
Current: 731.78
1.27
2740.96
EV-to-EBIT -26.92
ABEO's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ABEO: -26.92 )
Ranked among companies with meaningful EV-to-EBIT only.
ABEO' s EV-to-EBIT Range Over the Past 10 Years
Min: -112.3  Med: -4.2 Max: 2
Current: -26.92
-112.3
2
EV-to-EBITDA -27.83
ABEO's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ABEO: -27.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABEO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -114.8  Med: -4.4 Max: 2
Current: -27.83
-114.8
2
EV-to-Revenue 793.39
ABEO's EV-to-Revenue is ranked lower than
92% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ABEO: 793.39 )
Ranked among companies with meaningful EV-to-Revenue only.
ABEO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 71.9 Max: 5351.7
Current: 793.39
1.2
5351.7
Current Ratio 22.13
ABEO's Current Ratio is ranked higher than
87% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ABEO: 22.13 )
Ranked among companies with meaningful Current Ratio only.
ABEO' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.1 Max: 27.83
Current: 22.13
0.02
27.83
Quick Ratio 22.13
ABEO's Quick Ratio is ranked higher than
88% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ABEO: 22.13 )
Ranked among companies with meaningful Quick Ratio only.
ABEO' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.1 Max: 27.83
Current: 22.13
0.02
27.83
Days Sales Outstanding 46.14
ABEO's Days Sales Outstanding is ranked higher than
70% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ABEO: 46.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.23  Med: 58.5 Max: 6185.79
Current: 46.14
13.23
6185.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -328.90
ABEO's 3-Year Average Share Buyback Ratio is ranked lower than
99% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ABEO: -328.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABEO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -328.9  Med: -11.9 Max: 0
Current: -328.9
-328.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.98
ABEO's Price-to-Net-Cash is ranked lower than
68% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ABEO: 12.98 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABEO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.28  Med: 6.11 Max: 110.58
Current: 12.98
3.28
110.58
Price-to-Net-Current-Asset-Value 12.58
ABEO's Price-to-Net-Current-Asset-Value is ranked lower than
72% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ABEO: 12.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABEO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.2  Med: 5.75 Max: 119.9
Current: 12.58
3.2
119.9
Price-to-Tangible-Book 12.38
ABEO's Price-to-Tangible-Book is ranked lower than
80% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ABEO: 12.38 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABEO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 5.07 Max: 40
Current: 12.38
3.14
40
Price-to-Median-PS-Value 11.26
ABEO's Price-to-Median-PS-Value is ranked lower than
98% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ABEO: 11.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABEO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.17 Max: 874.13
Current: 11.26
0.02
874.13
Earnings Yield (Greenblatt) % -3.70
ABEO's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ABEO: -3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABEO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -438.8  Med: -21.8 Max: 78.5
Current: -3.7
-438.8
78.5

More Statistics

Revenue (TTM) (Mil) $0.88
EPS (TTM) $ -0.66
Beta2.64
Short Percentage of Float26.40%
52-Week Range $4.05 - 22.75
Shares Outstanding (Mil)46.78

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1 1 11 373
EPS ($) -0.67 -0.76 -0.62 5.11
EPS without NRI ($) -0.67 -0.76 -0.62 5.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}